Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of NDI-225673 in inflammatory bowel disease
NL-OMON61663Phase 1Recruiting
- Sponsor
- Nimbus Salacia
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of NDI-225673 in inflammatory bowel disease (IBD), sponsored by Nimbus Salacia. Started Oct 2026; status: recruiting.
02
Drugs
NDI-225673
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON61663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61663.